.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Citi
Colorcon
Accenture
Deloitte
Harvard Business School
Medtronic
AstraZeneca
Merck
Mallinckrodt

Generated: September 21, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Pharmaceutical formulation for slow release via controlled surface erosion
Abstract:A pharmaceutical composition in tablet form for oral administration comprises: (a) 30-90% by weight of an active ingredient having a water solubility (20.degree. C.) of about 1/10-1/500 (w/w); (b) 1-40% by weight of an excipient which is pharmaceutically acceptable in oral tablets and which has a water solubility (20.degree. C.) of about 1/1-1/20 (w/w); (c) 0-20% by weight of a binder which is pharmaceutically acceptable in oral tablets; (d) 0-50% by weight of an excipient which is pharmaceutically acceptable in oral tablets and which has a water solubility (20.degree. C.) of about 1/1-1/5 (w/w); (e) 0.5-5% by weight of a die wall lubricant pharmaceutically acceptable in oral tablets; (f) 0-5% by weight of a surface active agent pharmaceutically acceptable in oral tablets; and (g) 0-1.0% by weight of a disintegration agent pharmaceutically acceptable in oral tablets; whereby the active ingredient has a slow in vivo release rate due to controlled surface erosion of the tablet.
Inventor(s): Powell; David R. (Baudette, MN), Patel; Vithal K. (Baudette, MN)
Assignee: Rowell Laboratories, Inc. (Baudette, MN)
Application Number:06/040,789
Patent Claims: 1. A pharmaceutical composition in tablet form for oral administration consisting essentially of

(a) 70-80 wt.% of lithium carbonate;

(b) 5-15 wt.% of an excipient which is pharmaceutically acceptable in oral tablets and which has a water solubility (20.degree. C.) of about 1/1-1/20 (w/w);

(c) 2-7 wt.% of a binder which is pharmaceutically acceptable in oral tablets;

(d) 5-15 wt.% of an excipient which is pharmaceutically acceptable in oral tablets and which has a water solubility (20.degree. C.) of about 1/1-1/5 (w/w);

(e) 0.9-3.3 wt.% of a dye wall lubricant pharmaceutically acceptable in oral tablets;

(f) 0.1-0.2 wt% of a surface active agent pharmaceutically acceptable in oral tablets; and

(g) 0.15-0.35 wt.% of a disintegration agent pharmaceutically acceptable in oral tablets;

whereby the active ingredient has a slow zero order in vivo release rate and a plasma concentration/time curve of substantially the same shape as that of FIG. 1, due to controlled surface erosion of the tablet.

2. The pharmaceutical composition of claim 1 consisting essentially of: 70-80 wt.% of lithium carbonate; 5-15 wt.% of sodium chloride; 2-7 wt.% of polyvinylpyrrolidone; 5-15 wt.% of sorbitol; 0.9-3.3 wt.% of calcium stearate; 0.1-0.2 wt.% of sodium lauryl sulfate; and 0.15-0.35 wt.% of sodium starch glycolate.

3. The pharmaceutical composition of claim 2 consisting essentially of the following approximate amounts of ingredients: 300 mg of lithium carbonate; 40 mg of sodium chloride; 15 mg of polyvinylpyrrolidone; 9.4 mg of calcium stearate; 0.6 mg of sodium lauryl sulfate; 40 mg of sorbitol; and 1 mg of sodium starch glycolate.

4. The pharmaceutical composition of claim 1, 2 or 3 which is in the form of a tablet of a hardness of 5-20 kg.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Express Scripts
Queensland Health
Chubb
Julphar
Farmers Insurance
McKesson
Chinese Patent Office
McKinsey
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot